Emergency Medicine Doctors in Kennewick, WA Accepting Medicare

9 Emergency Medicine doctors found. Showing 1 - 9

Kenneth J Egli, MD Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 8508 W Gage Blvd Ste A101, Kennewick, WA 99336 Phone: 877-522-1275    Fax: 833-888-7145

Edward Salko, DO Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 3810 Plaza Way, Kennewick, WA 99338 Phone: 509-737-1492

Kevin Gurney, D.O. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 900 S Auburn St, Kennewick, WA 99336 Phone: 509-586-6111

Tobun Toby Cheung, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 3810 Plaza Way, Kennewick, WA 99338 Phone: 509-221-7010

Jose Luis Loera, M.D. Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 900 S Auburn St, Kennewick, WA 99336 Phone: 509-586-6111

Ethan Estoos, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 3810 Plaza Way, Kennewick, WA 99338 Phone: 509-221-5980

Louis K Koussa, D.O. Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 900 S Auburn Street, Kennewick, WA 99336 Phone: 509-586-6111

Dr. Lysle Westley Williams Jr., M.D. Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 3000 W Kennewick Ave, Kennewick, WA 99336 Phone: 509-783-8700    Fax: 509-783-2933

Dr. Brian K. Barstad, M.D. Emergency Medicine - Emergency Medical Services Medicare: Accepting Medicare Assignments Practice Location: 4804 W Clearwater Ave, Kennewick, WA 99336 Phone: 509-942-2355    Fax: 509-222-1289

News Archive

Vical extends relationship with U.S. NMRC for emerging disease vaccine platform

Vical Incorporated announced today that the company has extended its relationship with the U.S. Naval Medical Research Center to develop its platform technology for the rapid development and production of vaccines against emerging infectious diseases.

Enzo commences clinical trial of Optiquel for chronic non-infectious uveitis

Enzo Biochem, Inc., announced today that, following filing of a investigational new drug (IND) application with the FDA, its Enzo Therapeutics division is commencing a clinical trial of Optiquel™ , the Company's proprietary oral therapeutic for chronic non-infectious uveitis. The trial is designed as a randomized, double-masked, placebo-controlled study with a long-term follow-up and is being conducted by the National Institute of Health's National Eye Institute (NEI).

Study examines how pregnancy risk factors affect outcomes of home and birthing center deliveries

Women with some characteristics commonly thought to increase pregnancy risks - being over age 35; being overweight; and in some cases, having a vaginal birth after a cesarean section - tend to have good outcomes when they give birth at home or in a birth center, a new assessment has found.

Abattis receives Intl Class 5 Trademark for DefenZall in the U.S. and Taiwan

Abattis Bioceuticals Corp., announces it has been granted Intl Class 5 Trademark for DefenZall in Taiwan and the USA.

Read more Medical News

› Verified 2 days ago